Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases

International Journal of Cardiology

Volumn 148, Issue 2, 2011, Pages 131-138

  Feher, Andrea ^a   Pusch, Gabriella ^a   Koltai, Katalin ^a   Tibold, Antal ^a   Gasztonyi, Beata ^b   Szapary, Laszlo ^a   Feher, Gergely ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Zala County Hospital   (Hungary)

Author keywords

Cerebrovascular disease; Primary prevention; Secondary prevention; Statin; Stroke; Transient ischaemic attack

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MONOTHERAPY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

BRAIN ISCHEMIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; MORBIDITY; RISK FACTORS; STROKE;

EID: 79953243673     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.012     Document Type: Review

References (51)

1. S. Lewington, G. Whitlock, and R. Clarke Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths Lancet 370 2007 1829 1839
2. M.R. Cobain, M.J. Pencina, R.B. D'Agostino Sr., and R.S. Vasan Lifetime risk for developing dyslipidemia: the Framingham Offspring Study Am J Med 120 2007 623 630
3. E.J. Mills, B. Rachlis, P. Wu, P.J. Devereaux, P. Arora, and D. Perri Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, 000 patients J Am Coll Cardiol 52 22 2008 1769 1781
4. P. Amarenco, and J. Labreuche Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention Lancet Neurol 8 5 2009 453 463
5. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
6. Z. Zhou, E. Rahme, and L. Pilote Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Am Heart J 151 2006 273 281 (Pubitemid 43144726)
7. P. Thavendiranathan, A. Bagai, M.A. Brookhart, and N.K. Choudhry Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials Arch Intern Med 166 2006 2307 2313 (Pubitemid 44833354)
8. S. Ward, M. Lloyd Jones, and A. Pandor A systematic review and economic evaluation of statins for the prevention of coronary events Health Technol Assess 11 2007 1 160 iii-iv
9. H.M.G. Co A Reductase Inhibitors (Statins) in the Primary Prevention of Cardiovascular Disease 2007 Canadian Agency for Drugs and Technologies in Health Vancouver, British Columbia
10. C. O'Regan, P. Wu, P. Arora, D. Perri, and E.J. Mills Statin therapy in stroke prevention: a meta-analysis involving 121, 000 patients Am J Med 121 1 2008 24 33
11. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
12. P. Amarenco, J. Bogousslavsky, and A. Callahan III Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 6 2006 549 559
13. K.M. Welch Review of the SPARCL trial and its subanalyses Curr Atheroscler Rep 11 4 2009 315 321
14. P. Amarenco, O. Benavente, and L.B. Goldstein Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes Stroke 40 4 2009 1405 1409
15. P. Amarenco, L.B. Goldstein, and A. Callahan III Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Atherosclerosis 204 2 2009 515 520
16. H. Sillesen, P. Amarenco, and M.G. Hennerici Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Stroke 39 12 2008 3297 3302
17. L.B. Goldstein, P. Amarenco, and M. Lamonte Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Stroke 39 9 2008 2444 2448
18. L.B. Goldstein, P. Amarenco, and J. Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Stroke 40 11 2009 3526 3531
19. BN Manktelow, and J.F. Potter Interventions in the management of serum lipids for preventing stroke recurrence Cochrane Database Syst Rev 2009 (3):CD002091
20. P. Amarenco, L.B. Goldstein, and M. Messig Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial Stroke 40 7 2009 2486 2492
21. S.E. Nissen, S.J. Nicholls, and I. Sipahi Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 13 2006 1556 1565
22. J.R. Crouse III, J.S. Raichlen, and W.A. Riley Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 12 2007 1344 1353 (Pubitemid 46513235)
23. P.H. Jones, D.B. Hunninghake, and K.C. Ferdinand Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial Clin Ther 26 9 2004 1388 1399 (Pubitemid 39572153)
24. K.M. Fox, S.K. Gandhi, R.L. Ohsfeldt, J.W. Blasetto, and M.H. Davidson Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database Clin Ther 29 11 2007 Nov 2385 2394 (Pubitemid 350298128)
25. H. Schuster Improving lipid management-to titrate, combine or switch Int J Clin Pract 58 2004 689 694 (Pubitemid 39144584)
26. M. Costa-Scharplatz, K. Ramanathan, T. Frial, B. Beamer, and S. Gandhi Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Clin Ther 30 7 2008 1345 1357
27. S. Ward, M. Lloyd Jones, and A. Pandor A systematic review and economic evaluation of statins for the prevention of coronary events Health Technol Assess 11 14 2007 1 160 iii-iv
28. Y.B. Tran, T. Frial, and P.S. Miller Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins Can J Clin Pharmacol 14 2 2007 e205 e214
29. Canadian Pharmacists Association Compendium of pharmaceuticals and specialties 2006 Canadian Pharmacists Association Ottawa
30. J. Wlodarczyk, D. Sullivan, and M. Smith Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials Am J Cardiol 102 12 2008 1654 1662
31. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 22 2009 2113 2122
32. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy. Ann Intern Med in press [2009 Aug 31, Electronic publication ahead of print].
33. J.J. Kastelein, F. Akdim, and E.S. Stroes Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 14 2008 1431 1443 (Pubitemid 351482735)
34. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 22 2009 2113 2122
35. T.C. Villines, E.J. Stanek, and P.J. Devine The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration J Am Coll Cardiol Apr 8 2010 10.1016/j.jacc.2010.03.017
36. The ACCORD Study Group Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus Published at www.nejm.org March 14, 2010 (10.1056/ NEJMoa1001282).
37. C.P. Cannon, R.P. Giugliano, and M.A. Blazing Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 5 2008 826 832
38. R.M. Califf, Y. Lokhnygina, and C.P. Cannon An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 5 2010 705 709
39. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
40. V. Narla, M.J. Blaha, R.S. Blumenthal, and E.D. Michos The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences Vasc Health Risk Manage 5 2009 1033 1042
41. B.M. Everett, R.J. Glynn, J.G. MacFadyen, and P.M. Ridker Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Circulation 121 1 2010 143 150
42. P.M. Ridker, J.G. MacFadyen, and F.A. Fonseca Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes 2 6 Nov 2009 616 623
43. K. Mayanagi, P.V. Katakam, T. Gáspár, F. Domoki, and D.W. Busija Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia J Cereb Blood Flow Metab 28 12 2008 1927 1935
44. J.S. Nicholas, C.J. Swearingen, J.C. Thomas, Z. Rumboldt, P. Tumminello, and S.J. Patel The effect of statin pretreatment on infarct volume in ischemic stroke Neuroepidemiology 31 1 2008 48 56 (Pubitemid 351957398)
45. A.Y. Yu, M.R. Keezer, B. Zhu, C. Wolfson, and R. Côté Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes Cerebrovasc Dis 27 4 2009 398 402
46. B. Fuentes, P. Martínez-Sánchez, and E. Díez-Tejedor Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome Cerebrovasc Dis 27 Suppl 1 2009 126 133
47. M. Blanco, F. Nombela, and M. Castellanos Statin treatment withdrawal in ischemic stroke: a controlled randomized study Neurology 69 9 2007 904 910 (Pubitemid 47329591)
48. I. Miedema, M. Uyttenboogaart, K. Koopman, J. De Keyser, and G.J. Luijckx Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke Cerebrovasc Dis 29 3 2010 Feb 263 267
49. L. Restrepo, O.Y. Bang, and B. Ovbiagele Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy Cerebrovasc Dis 28 4 2009 384 390
50. N. Meier, K. Nedeltchev, and C. Brekenfeld Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke Stroke 40 5 2009 1729 1737
51. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150